Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) Shares Outstanding (Diluted Average) (2018 - 2025)

Neurogene's Shares Outstanding (Diluted Average) history spans 6 years, with the latest figure at $21.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 21.4% year-over-year to $21.3 million; the TTM value through Dec 2025 reached $21.3 million, up 21.4%, while the annual FY2025 figure was $21.3 million, 21.4% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $21.3 million in Q4 2025 per NGNE's latest filing, up from $21.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $21.3 million in Q4 2025 to a low of $433623.0 in Q1 2023.
  • Average Shares Outstanding (Diluted Average) over 3 years is $13.2 million, with a median of $16.9 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Diluted Average): surged 3798.26% in 2024, then rose 21.4% in 2025.
  • A 3-year view of Shares Outstanding (Diluted Average) shows it stood at $4.7 million in 2023, then skyrocketed by 277.22% to $17.6 million in 2024, then rose by 21.4% to $21.3 million in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Shares Outstanding (Diluted Average) are $21.3 million (Q4 2025), $21.1 million (Q3 2025), and $21.0 million (Q2 2025).